European Pharmaceutical Review

AUGUST 24, 2022

ANTIBODY-DRUG conjugates (ADCs) are therapeutic molecules designed as highly targeted medicines with the promise of changing the way we treat cancer and other diseases. An ADC combines the specificity of an antibody and the potent power of an anti?cancer cancer agent or disease-relevant toxin. necks inhibiting these first?generation

Engineering 82

Engineering Side effects Marketing Patients 82

pharmaphorum

JULY 25, 2022

” GSK’s antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) was the first BCMA-targeting drug to reach the market in 2020, and has since been joined by Carvykti as well as Bristol-Myers Squibb and bluebird bio rival CAR-T therapy Abecma (idecabtagene vicleucel). .”

Medicine 52

Medicine FDA Recruitment Patients 52

European Pharmaceutical Review

NOVEMBER 10, 2022

Complex medicines offer diverse therapeutic modalities, including RNA therapeutics and antibody-drug conjugates (ADCs). BT-474 cell line was gene-edited to incorporate a green fluorescent protein (GFP) tag into late endosomes/lysosomes (green). Physical characterisation.

Medicine 95

Medicine Distribution Engineering Electronics 95